Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $392.6 million.

  • Krystal Biotech's Cash & Equivalents rose 498.39% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 498.39%. This contributed to the annual value of $344.9 million for FY2024, which is 375.72% down from last year.
  • Latest data reveals that Krystal Biotech reported Cash & Equivalents of $392.6 million as of Q3 2025, which was up 498.39% from $353.8 million recorded in Q2 2025.
  • Krystal Biotech's Cash & Equivalents' 5-year high stood at $402.2 million during Q1 2021, with a 5-year trough of $140.7 million in Q1 2023.
  • For the 5-year period, Krystal Biotech's Cash & Equivalents averaged around $306.5 million, with its median value being $341.2 million (2021).
  • Per our database at Business Quant, Krystal Biotech's Cash & Equivalents tumbled by 5255.62% in 2022 and then skyrocketed by 15507.55% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Cash & Equivalents stood at $341.2 million in 2021, then crashed by 52.56% to $161.9 million in 2022, then skyrocketed by 121.33% to $358.3 million in 2023, then dropped by 3.76% to $344.9 million in 2024, then rose by 13.84% to $392.6 million in 2025.
  • Its Cash & Equivalents stands at $392.6 million for Q3 2025, versus $353.8 million for Q2 2025 and $308.8 million for Q1 2025.